Januvia is a brand name of sitagliptin, approved by the FDA in the following formulation(s):
JANUVIA (sitagliptin phosphate - tablet; oral)
Manufacturer: MERCK CO INC
Approval date: October 16, 2006
Strength(s): EQ 100MG BASE [RLD], EQ 25MG BASE, EQ 50MG BASE
Has a generic version of Januvia been approved?
No. There is currently no therapeutically equivalent version of Januvia available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Januvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Patent 6,303,661
Issued: October 16, 2001
Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
Assignee(s): Probiodrug
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.Patent expiration dates:
- April 24, 2017✓
- April 24, 2017
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Patent 6,699,871
Issued: March 2, 2004
Inventor(s): Scott D.; Edmondson & Michael H.; Fisher & Dooseop; Kim & Malcolm; Maccoss & Emma R.; Parmee & Ann E.; Weber & Jinyou; Xu
Assignee(s): Merck & Co., Inc.
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Patent expiration dates:
- July 26, 2022✓✓✓
- July 26, 2022
Method of regulating glucose metabolism, and reagents related thereto
Patent 6,890,898
Issued: May 10, 2005
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
1149336 Ontario Inc.
New England Medical Center Hospitals, Inc.
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Patent expiration dates:
- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019
Method of regulating glucose metabolism, and reagents related thereto
Patent 7,078,381
Issued: July 18, 2006
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.Patent expiration dates:
- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Patent 7,125,873
Issued: October 24, 2006
Inventor(s): Edmondson; Scott D & Fisher; Michael H. & Kim; Dooseop & Maccoss; Malcolm & Parmee; Emma R. & Weber; Ann E & Xu; Jinyou
Assignee(s): Merck & Co., Inc.
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Patent expiration dates:
- July 26, 2022✓
- July 26, 2022✓
- July 26, 2022✓
- July 26, 2022✓
- July 26, 2022
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Patent 7,326,708
Issued: February 5, 2008
Inventor(s): Cypes; Stephen Howard & Chen; Alex Minhua & Ferlita; Russell R. & Hansen; Karl & Lee; Ivan & Vydra; Vicky K. & Wenslow, Jr.; Robert M.
Assignee(s): Merck & Co., Inc.
The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.Patent expiration dates:
- April 11, 2026✓✓✓
- April 11, 2026
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 12, 2010 - DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- October 12, 2010 - RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- October 16, 2011 - NEW CHEMICAL ENTITY
See also...
- Januvia Consumer Information (Drugs.com)
- Januvia Consumer Information (Wolters Kluwer)
- Januvia Consumer Information (Cerner Multum)
- Januvia Advanced Consumer Information (Micromedex)
- Januvia AHFS DI Monographs (ASHP)
- Sitagliptin Consumer Information (Wolters Kluwer)
- Sitagliptin Consumer Information (Cerner Multum)
- Sitagliptin Advanced Consumer Information (Micromedex)
- Sitagliptin Phosphate AHFS DI Monographs (ASHP)
No comments:
Post a Comment